For generations, pancreatic cancer has occupied a grim corner of medicine where the tools of modern oncology arrived and found little purchase — its dominant mutation, KRAS, long declared undruggable. Now, a phase 3 trial of daraxonrasib, a drug that reaches KRAS indirectly through a molecular intermediary, has nearly doubled median survival in advanced disease, extending it from 6.7 to 13.2 months in 500 patients. The result does not promise a cure, but it signals that a molecular wall long thought permanent has begun, at last, to give way.
Daraxonrasib Doubles Survival in Advanced Pancreatic Cancer, Targeting Long-Elusive KRAS
Advanced pancreatic cancer patients historically face median survival of 6.7 months; this trial offers potential to extend survival and improve quality of life for thousands of patients.
one of pancreatic cancer's most important targets is no longer out of reach
Mark
Why did KRAS seem so impossible to target for so long?
Mimi
The protein's surface just didn't have the right shape. Drugs work by fitting into pockets on proteins, like a key in a lock. KRAS didn't have those pockets. It was like trying to grab something smooth with nothing to grip.
Mark
So how does daraxonrasib actually work if it can't bind to KRAS directly?
Mimi
It's clever. The drug grabs onto a different molecule—cyclophilin A—and that complex is what actually disables KRAS. It's an indirect route, but it works.
Mark
The survival numbers are striking. But what about the side effects? More than 86 percent got a rash.
Mimi
True, but here's what matters: patients on daraxonrasib were less likely to quit treatment because of toxicity than those on chemotherapy. They also had less pain and better quality of life. A rash is manageable. Chemotherapy is brutal.
Mark
What happens now?
Mimi
Regulatory approval. If it clears, this could reshape how we treat pancreatic cancer. But it won't be a cure. Resistance will probably develop, and doctors will likely combine it with other drugs. Still, it's a real shift.
Der Puls
- Advanced pancreatic cancer has resisted targeted therapy for decades because KRAS — the mutation driving 90% of tumors — offered no surface for drugs to grip, leaving patients with chemotherapy as their only option.
- A 500-patient phase 3 trial of daraxonrasib produced a result rarely seen in this disease: median survival nearly doubled, and the risk of death fell by 60% compared to standard chemotherapy.
- The drug works as a daily oral tablet, and despite frequent side effects like skin rash and mouth sores, patients were less likely to quit treatment due to severe toxicity than those on chemotherapy — and reported less pain.
- Regulatory approval is now the critical threshold; if cleared, daraxonrasib could redirect pancreatic cancer care toward precision medicine, though resistance and the need for combination strategies remain open challenges.
For generations, pancreatic cancer has occupied a grim corner of medicine where the tools of modern oncology arrived and found little purchase — its dominant mutation, KRAS, long declared undruggable. Now, a phase 3 trial of daraxonrasib, a drug that reaches KRAS indirectly through a molecular intermediary, has nearly doubled median survival in advanced disease, extending it from 6.7 to 13.2 months in 500 patients. The result does not promise a cure, but it signals that a molecular wall long thought permanent has begun, at last, to give way.
Pancreatic cancer has long defied the advances that reshaped treatment for other cancers. The culprit is molecular: more than nine in ten pancreatic tumors carry mutations in KRAS, a gene that functions like a jammed accelerator, driving relentless cell division. For years, KRAS was considered undruggable — its protein offered no foothold for therapeutic molecules — and patients with advanced disease were left with chemotherapy, a treatment that slows progression but carries significant toxicity and eventually fails.
Daraxonrasib found a workaround. Rather than attacking KRAS directly, it binds to a molecule called cyclophilin A, which then engages and silences the mutant KRAS signal. In a phase 3 trial of 500 patients with metastatic pancreatic cancer who had already undergone prior treatment, the drug nearly doubled median survival — from 6.7 months on standard chemotherapy to 13.2 months — while cutting the risk of death by 60 percent.
The drug is taken as a daily oral tablet. Side effects were common, with skin rash affecting more than 86 percent of patients, alongside mouth sores, diarrhea, and nausea. Yet patients on daraxonrasib were less likely to discontinue treatment due to severe toxicity than those receiving chemotherapy, and they reported better quality of life and less pain — a detail that gives meaning to what those additional months actually represent.
Daraxonrasib now awaits regulatory review. Approval would not render pancreatic cancer manageable overnight — resistance may still emerge, and combination therapies will likely be needed — but it would mark a genuine turning point, demonstrating that one of oncology's most entrenched barriers is no longer absolute.
For decades, pancreatic cancer has been a disease that resisted the tools medicine had built to fight it. The reason sits at the molecular level: more than nine in ten pancreatic tumors are driven by mutations in a gene called KRAS, which acts like a stuck accelerator, telling cancer cells to keep dividing without pause. For a long time, KRAS seemed impossible to drug. Its protein structure lacked the binding pockets that molecules need to attach and disable it. Researchers called it undruggable. That left patients with advanced pancreatic cancer dependent on chemotherapy—a blunt instrument that slows disease but carries heavy toxicity and often fails as resistance builds.
Daraxonrasib takes a different path. Instead of trying to bind directly to KRAS, the drug latches onto a molecule called cyclophilin A. That complex then engages with active KRAS and silences its cancer-driving signal. In a phase 3 trial involving 500 patients with metastatic pancreatic cancer who had already received prior treatment, the results were striking. Median survival nearly doubled: from 6.7 months with standard chemotherapy to 13.2 months with daraxonrasib. The drug reduced the risk of death by 60 percent. For a disease as aggressive as advanced pancreatic cancer, that represents the kind of shift researchers have been pursuing for years.
The drug is taken as a daily oral tablet, which matters for quality of life. Side effects were common—skin rash appeared in more than 86 percent of patients, and mouth sores, diarrhea, nausea, and vomiting occurred regularly. Yet patients on daraxonrasib were actually less likely to abandon treatment because of severe toxicity than those receiving chemotherapy. They also reported better overall quality of life and less pain, a detail that speaks to something beyond survival numbers: what those extra months actually feel like to live.
What comes next is regulatory review. If daraxonrasib wins approval, it could mark a turning point toward more precise, targeted treatment for pancreatic cancer. The drug will not make this disease simple to manage. Resistance may still emerge, and combinations with other therapies will likely be necessary. But it demonstrates that one of pancreatic cancer's most formidable obstacles is no longer beyond reach.
Bemerkenswerte Zitate
For this disease, that is not a marginal result. It is the kind of change researchers have been chasing for years.— Trial findings
Möchten Sie die ganze Geschichte?
Das Original lesen bei diabetes.co.uk ↗
Health & Medicine